First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

<p>Abstract</p> <p>This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765,...

Full description

Bibliographic Details
Main Authors: Siu Lillian L, Molckovsky Andrea
Format: Article
Language:English
Published: BMC 2008-10-01
Series:Journal of Hematology & Oncology
Online Access:http://www.jhoonline.org/content/1/1/20
id doaj-a40c77d08ac643bf89c6162717fd11f6
record_format Article
spelling doaj-a40c77d08ac643bf89c6162717fd11f62020-11-24T21:36:34ZengBMCJournal of Hematology & Oncology1756-87222008-10-01112010.1186/1756-8722-1-20First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meetingSiu Lillian LMolckovsky Andrea<p>Abstract</p> <p>This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.</p> http://www.jhoonline.org/content/1/1/20
collection DOAJ
language English
format Article
sources DOAJ
author Siu Lillian L
Molckovsky Andrea
spellingShingle Siu Lillian L
Molckovsky Andrea
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Journal of Hematology & Oncology
author_facet Siu Lillian L
Molckovsky Andrea
author_sort Siu Lillian L
title First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_short First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_full First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_fullStr First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_full_unstemmed First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
title_sort first-in-class, first-in-human phase i results of targeted agents: highlights of the 2008 american society of clinical oncology meeting
publisher BMC
series Journal of Hematology & Oncology
issn 1756-8722
publishDate 2008-10-01
description <p>Abstract</p> <p>This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.</p>
url http://www.jhoonline.org/content/1/1/20
work_keys_str_mv AT siulillianl firstinclassfirstinhumanphaseiresultsoftargetedagentshighlightsofthe2008americansocietyofclinicaloncologymeeting
AT molckovskyandrea firstinclassfirstinhumanphaseiresultsoftargetedagentshighlightsofthe2008americansocietyofclinicaloncologymeeting
_version_ 1725940620343640064

Similar Items